title: Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
abstract: Parkinson's disease affects up to 1 million people in the US, most of them elderly. Motor and non-motor symptoms can be significantly disabling to the point of necessitating institutionalisation. Age-related changes in drug absorption, distribution, metabolism and excretion complicate the treatment of elderly patients with Parkinson's disease. General management principles include initiation of medication at low doses with gradual titration based on clinical effects, avoidance of certain classes of drugs (e.g. anticholinergics), and attention to polypharmacy and its risk for potentially toxic drug interactions. Levodopa remains the most efficacious anti-Parkinson's disease medication and should be the cornerstone of therapy in the elderly Parkinson's disease patient. Use of dopamine receptor agonists, amantadine and anticholinergic drugs in the elderly is limited by high risk for psychotoxicity. Catechol-O-methyltransferase inhibitors may be used to augment levodopa in the setting of 'wearing off' (i.e. motor fluctuations). Monoamine oxidase type B (MAO-B) inhibitors can be used across the spectrum of disease severity, but selegiline (deprenyl), the prototype in this class, is characterised by low and erratic bioavailability of the parent drug and conversion to amphetamine metabolites that may increase the risk of adverse events. A new orally disintegrating tablet formulation overcomes some of these limitations. Rasagiline is a new, selective, second-generation MAO-B inhibitor that is chemically and metabolically distinct from selegiline. The favourable safety profile of rasagiline in the elderly and its once-daily formulation may maximise drug adherence and improve outcomes.
authors: Movement Disorders Center, Schools of Medicine and Pharmacy, Loma Linda University, Loma Linda, California 92350, USA. jjchen@llu.edu
authors: Jack J
authors: JJ
authors: Chen
authors: Hubert H
authors: HH
authors: Fernandez
mesh_terms: D000368:Aged; D000375:Aging; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists / Q000627:therapeutic use; D006707:Homes for the Aged; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009735:Nursing Homes; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline; D012642:Selegiline; D007980:Levodopa
references: Neurology. 2002 Feb 26;58(4 Suppl 1):S79-86
references: 11909989
references: Geriatrics. 2001 Aug;56(8):24-5, 29-30, 33-5
references: 11505857
references: Parkinsonism Relat Disord. 2000 Nov 1;7(1):41-50
references: 11008195
references: Neurology. 2006 Apr 25;66(8):1200-6
references: 16540603
references: Neurology. 1995 Apr;45(4):669-71
references: 7723953
references: J Clin Psychopharmacol. 2003 Apr;23 (2):113-8
references: 12640211
references: J Neural Transm (Vienna). 2003 Nov;110(11):1241-55
references: 14628189
references: Arch Neurol. 2002 Dec;59(12):1937-43
references: 12470183
references: Neurol Clin. 2004 Oct;22(3 Suppl):S91-S106
references: 15501368
references: Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1260-5
references: 17548694
references: J Neurol Neurosurg Psychiatry. 1997 Aug;63(2):228-34
references: 9285463
references: Ann Neurol. 2002 Jun;51(6):722-9
references: 12112078
references: Neurosci Lett. 2004 Jan 30;355(3):169-72
references: 14732458
references: Drugs Aging. 1998 Nov;13(5):341-55
references: 9829163
references: Neurology. 1991 Feb;41(2 ( Pt 1)):202-5
references: 1992362
references: Drugs Aging. 2005;22(9):731-40
references: 16156677
references: Exp Gerontol. 2004 Nov-Dec;39(11-12):1731-8
references: 15582289
references: Mov Disord. 2003 Jun;18(6):659-67
references: 12784269
references: N Engl J Med. 2005 Sep 8;353(10):1021-7
references: 16148287
references: Fundam Clin Pharmacol. 2005 Apr;19(2):133-46
references: 15810893
references: Lancet. 2002 Nov 30;360(9347):1767-9
references: 12480442
references: Int J Geriatr Psychiatry. 2004 Jan;19(1):1-8
references: 14716693
references: Acta Neurol Scand Suppl. 1989;126:113-8
references: 2515716
references: Neurology. 2006 May 9;66(9):1427-9
references: 16682679
references: Ann Neurol. 2002 May;51(5):604-12
references: 12112107
references: J Neural Transm Suppl. 2006;(71):53-65
references: 17447416
references: Neurology. 2002 Jan 8;58(1):11-7
references: 11781398
references: Mayo Clin Proc. 2002 Sep;77(9):918-25
references: 12233925
references: Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:41-9
references: 15496222
references: J Neurochem. 1996 Oct;67(4):1532-9
references: 8858937
references: Neurology. 2002 Feb 26;58(4 Suppl 1):S19-32
references: 11909982
references: J Geriatr Psychiatry Neurol. 2004 Mar;17(1):39-41
references: 15018697
references: J Neural Transm Suppl. 1983;19:265-72
references: 6421992
references: N Engl J Med. 2007 Jan 4;356(1):39-46
references: 17202454
references: Clin Neuropharmacol. 1998 Mar-Apr;21(2):101-7
references: 9579296
references: Clin Neuropharmacol. 1998 May-Jun;21(3):169-75
references: 9617508
references: CNS Drugs. 2003;17(13):965-73
references: 14533946
references: N Engl J Med. 2007 Jan 4;356(1):29-38
references: 17202453
references: Drugs Aging. 2005;22(1):83-91; discussion 93-4
references: 15663351
references: Lancet. 1977 Oct 15;2(8042):791-5
references: 71602
references: J Neural Transm Suppl. 1998;52:287-300
references: 9564629
references: Lancet. 2002 May 4;359(9317):1589-98
references: 12047983
references: Expert Rev Neurother. 2005 Nov;5(6):811-21
references: 16274338
references: Neurology. 2004 Mar 23;62(6 Suppl 4):S27-31
references: 15037669
references: Neurology. 1998 Aug;51(2):520-5
references: 9710028
references: Clin Neuropharmacol. 2004 Jan-Feb;27(1):4-5
references: 15090928
references: Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898
references: 16034956
references: Arch Neurol. 2005 Feb;62(2):241-8
references: 15710852
references: Mov Disord. 2006 Apr;21(4):549-55
references: 16228997
references: Clin Pharmacokinet. 1997 Aug;33(2):91-102
references: 9260033
references: Mov Disord. 2005 Feb;20(2):190-9
references: 15551331
references: Mov Disord. 2000 Jul;15(4):664-8
references: 10928576
references: Pharmacotherapy. 1999 Nov;19(11):1321-7
references: 10555938
references: Neurology. 1997 Jul;49(1 Suppl 1):S34-48
references: 9222273
references: J Neurosci Nurs. 2003 Oct;35(5):242-51
references: 14593935
references: Lippincotts Prim Care Pract. 2000 Nov-Dec;4(6):595-607
references: 11933373
references: N Engl J Med. 2004 Dec 9;351(24):2498-508
references: 15590952
references: J Geriatr Psychiatry Neurol. 2004 Sep;17(3):127-36
references: 15312276
references: Arch Neurol. 2006 Jul;63(7):969-73
references: 16831966
references: Parkinsonism Relat Disord. 2002 Jun;8(5):369-80
references: 15177067
references: Arch Neurol. 1997 Nov;54(11):1393-8
references: 9362988
references: Mov Disord. 2001 May;16(3):507-10
references: 11391746
references: Arch Neurol. 2004 Apr;61(4):561-6
references: 15096406
references: Mov Disord. 1999 Mar;14(2):246-51
references: 10091617
references: Mov Disord. 2006 Mar;21(3):343-53
references: 16211594
references: J Neural Transm (Vienna). 2004 Oct;111(10-11):1303-15
references: 15480840
references: Clin Neuropharmacol. 2000 Sep-Oct;23(5):271-5
references: 11154095
references: Eur J Pharmacol. 2002 Jan 11;434(3):109-16
references: 11779573
references: Acta Neurol Scand Suppl. 1989;126:127-37
references: 2515718
references: Lancet. 2005 Mar 12-18;365(9463):947-54
references: 15766996
references: Arch Neurol. 2004 Jul;61(7):1044-53
references: 15262734
references: N Engl J Med. 2004 Dec 9;351(24):2509-18
references: 15590953
references: Med Sci Monit. 2002 Apr;8(4):CR241-6
references: 11951064
references: Neurotoxicology. 2004 Jan;25(1-2):243-50
references: 14697899
references: Mov Disord. 2007 Jan 15;22(2):234-8
references: 17094087
references: J Clin Pharmacol. 2005 Aug;45(8):878-94
references: 16027398
references: Drug Saf. 1998 Jul;19(1):11-22
references: 9673855
references: Mov Disord. 2004 Apr;19(4):426-32
references: 15077240
references: J Neurol Neurosurg Psychiatry. 1999 Sep;67(3):300-7
references: 10449550
references: Mov Disord. 2005 Mar;20(3):342-4
references: 15580606
references: Aust Fam Physician. 2003 Nov;32(11):927-31
references: 14650790
references: Arch Intern Med. 1997 Oct 13;157(18):2089-96
references: 9382665
references: Clin Pharmacol Ther. 1985 Feb;37(2):137-44
references: 3967456
references: Ann Pharmacother. 2002 Sep;36(9):1331-6
references: 12196047
references: Neurol Clin. 2004 Oct;22(3 Suppl):S63-90
references: 15501367
references: Anaesth Intensive Care. 2005 Apr;33(2):181-7
references: 15960399
references: J Neurol Neurosurg Psychiatry. 2006 May;77(5):585-9
references: 16614017
references: Brain. 1984 Jun;107 ( Pt 2):487-506
references: 6722513
references: Exp Gerontol. 2003 Aug;38(8):843-53
references: 12915206
references: J Clin Pharmacol. 2006 Aug;46(8):933-44
references: 16855078
references: J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42
references: 16222436
references: J Neural Transm Suppl. 1998;52:279-85
references: 9564628
references: Drug Saf. 2003;26(9):643-59
references: 12814332
references: Pharmacotherapy. 2000 Jan;20(1 Pt 2):33S-42S
references: 10641990
references: Arch Neurol. 2006 Feb;63(2):205-9
references: 16476808
references: J Neural Transm Suppl. 1987;25:123-9
references: 3123598
references: Neurology. 2006 Apr 11;66(7):983-95
references: 16606909
references: Neurology. 1997 Apr;48(4):1070-7
references: 9109902
references: Expert Opin Pharmacother. 2002 Apr;3(4):381-8
references: 11934340
references: J Am Geriatr Soc. 2000 Aug;48(8):938-42
references: 10968298
references: J Neurol Neurosurg Psychiatry. 2005 Jul;76(7):934-9
references: 15965198
references: Clin Neuropharmacol. 1993 Feb;16(1):83-7
references: 8422661
references: Parkinsonism Relat Disord. 2002 Oct;9(1):15-21
references: 12217618
references: J Neural Transm (Vienna). 2004 Oct;111(10-11):1343-63
references: 15340869
references: N Engl J Med. 1998 Oct 8;339(15):1044-53
references: 9761807
references: Mov Disord. 2006 Oct;21(10):1716-21
references: 16856145
references: Clin Neuropharmacol. 1988 Feb;11(1):45-55
references: 3127050
references: Drug Metab Dispos. 1997 Jun;25(6):657-62
references: 9193866
references: N Engl J Med. 1989 Nov 16;321(20):1364-71
references: 2509910
references: Mov Disord. 2001 May;16(3):448-58
references: 11391738
references: Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8
references: 9633680
references: Neurology. 1989 Nov;39(11 Suppl 2):11-9
references: 2685647